Call 911 or go to the emergency department if, after a biopsy, you pass blood clots in your urine, feel dizzy or faint, or develop back pain that is getting worse.
A kidney biopsy is a procedure that removes one or more thin cores of kidney tissue so they can be examined under a microscope. The cores are small, roughly the width of a thick thread and a centimetre or two long, and they are handled in a laboratory in several different ways rather than looked at once and filed away.
That laboratory work is the whole point. Tissue is usually examined by light microscopy, which shows the architecture of the filtering units, the tubules around them and the small blood vessels. It is also examined with immunofluorescence, which highlights immune proteins sitting in places they should not be, and often with electron microscopy, which resolves the layers of the filtering membrane at a scale no blood test can reach. A pathologist reports on how many filtering units are present, how many are scarred, whether there is active inflammation, and how much scarring sits in the tissue between the tubules.
Those details matter because kidney diseases that look identical from outside the body can be completely different on the slide. Two people can both have protein in the urine and a slowly falling filtering rate, and the tissue can show immune deposits in one and a quiet, scarred kidney in the other. Clinical overviews describe the biopsy as the step that establishes a tissue diagnosis, grades how active or chronic the process is, and informs what happens next 1.
It is a diagnostic procedure, not a therapeutic one. Nothing is repaired during a biopsy. What changes is the quality of the information a clinician is working from.
A biopsy is suggested when blood and urine tests have shown that something is wrong with the kidneys but cannot show what. Common triggers include persistent protein in the urine, blood in the urine that appears alongside protein, an unexplained fall in filtering function, kidney involvement in a systemic illness such as an autoimmune condition, and a kidney picture that is changing faster than the story around it would explain. Published reviews list these as the usual indications for sampling tissue from a native kidney 2.
The decision is rarely about curiosity. It is about whether the answer would change something. A clinician weighs three things. First, how likely it is that tissue will give a specific diagnosis. Second, whether that diagnosis would change the care plan, since some conditions call for a very different approach from others. Third, how the risk of the procedure compares with the cost of guessing. Overviews written for non-specialists frame the question in exactly this way, as a judgement about diagnostic value against procedural risk 1.
Diabetes is a good example of why the judgement is not automatic. Kidney damage in people with long-standing diabetes often follows a recognisable pattern, and when the pattern fits, tissue may add little. Research suggests that, in people with type 2 diabetes, biopsy is considered mainly when the clinical picture does not fit kidney disease caused by diabetes, for example when protein appears abruptly, when function falls unusually fast, or when there are signs pointing to a separate kidney disease on top 3.
The same logic applies in reverse. When a person is young, when the urine shows active inflammation, or when a systemic illness is already known, tissue often answers the question that no amount of repeat bloodwork will.
Creatinine is the blood marker that most often raises the question in the first place, because an unexplained rise is one of the standard reasons to look at tissue. Creatinine is a waste product of normal muscle turnover that healthy kidneys clear into the urine, so the level in blood tends to rise as filtering falls.
Your lab's own reference interval appears as printed on your lab report. FitScript's optimal range for creatinine is 0.8 to 1.2 mg/dL in men and 0.6 to 0.9 mg/dL in women, and optimal ranges are FitScript's optimization targets rather than diagnostic cut-offs. One reading on its own settles very little, since muscle mass, hydration and recent hard training all move the number. The parent guide covers what the marker measures, how it is tested and how to read a result in full.
The procedure itself is short, and almost all of the appointment is preparation and monitoring. Here is the usual sequence for a percutaneous, ultrasound guided biopsy of a native kidney.
First comes consent and a final safety check. Blood pressure is measured and recorded, recent blood counts and clotting results are reviewed, and the team confirms which medicines were paused and which were continued. A cannula may be placed in the arm.
You are then positioned lying face down, often with a firm pad under the abdomen to push the kidneys closer to the back wall. The operator uses ultrasound to find the kidney and to mark a path to its lower part, which contains more filtering units and fewer large vessels. The skin over that spot is cleaned and numbed, and the numbing medicine is given time to work down through the deeper tissue, which is the part people tend to feel.
The biopsy itself is taken with a spring loaded needle that fires and returns in a fraction of a second. You will be asked to take a breath in and hold still, because the kidney moves with breathing and the operator needs it stationary at the moment of the pass. There is a loud click. Most people describe pressure and a brief deep push rather than sharp pain. More than one core is usually taken so the laboratory has enough tissue for each type of examination, and in some centres a technician checks the sample under a microscope in the room to confirm that filtering units are present before the needle is put away.
A dressing goes on, you are rolled onto your back, and the monitoring period begins. Sedation, when it is used at all, is light and the aim is to keep you awake enough to follow the breathing instructions.
There is more than one way to reach kidney tissue, and the route is chosen around anatomy and bleeding risk rather than preference.
| Approach | How the sample is taken | When it may be considered |
|---|---|---|
| Percutaneous, ultrasound guided | A needle passes through the skin over the kidney into the lower part of the organ while the kidney is watched in real time | The standard route for sampling a native kidney in adults who can lie face down and follow breathing instructions |
| Percutaneous, CT guided | The same needle approach, using cross sectional imaging instead of ultrasound to locate the kidney and plan the path | When body shape, bowel gas or unusual anatomy makes the kidney hard to see clearly with ultrasound |
| Transjugular | A catheter is threaded from a vein in the neck into the kidney vein, and tissue is sampled from inside the vessel | When bleeding risk makes the route through the skin less attractive. Research suggests this route gives a usable diagnostic yield with a low rate of major bleeding in people selected for it 4 |
| Open or laparoscopic | Tissue is taken under direct vision in an operating room | When image guided sampling is not possible, or when earlier attempts have not produced enough usable tissue |
The transjugular route exists for a specific reason. A needle passing through the skin leaves the kidney surface and travels outwards, so any bleeding escapes into the space around the kidney. A sample taken from inside the vein travels the other way, so bleeding tends to drain back into the circulation rather than collecting outside the organ. That is why it is considered for people whose clotting is harder to manage.
Preparation is mostly about bleeding risk, blood pressure and logistics. Your team gives you the specific instructions, and those instructions override anything written here.
Blood tests before the day usually include a full blood count and clotting tests, along with a current creatinine and often a blood group and antibody screen in case a transfusion is ever needed. Blood pressure is checked and, when it is high, brought under control before the procedure goes ahead, because poorly controlled pressure is listed among the situations that make a percutaneous biopsy less suitable 2.
Medicines are the part people get wrong. Some medicines are paused before a biopsy and some are continued, and the decision depends on why you are taking them. Ask your prescriber well before the appointment, and never stop a medicine on your own. The same applies to anything you buy without a prescription, so bring a full list rather than editing it yourself.
You will usually be asked not to eat for a set period beforehand, with clear fluids allowed up to a stated time. Arrange a ride home, since you will not be driving afterwards, and arrange for an adult to stay with you for the first night. Wear something loose. Bring a book, because the waiting and the lying flat take far longer than the needle does.
If you take anything for pain, mention it, because some of those products affect clotting as well. Again, the instruction is to ask your prescriber rather than decide.
You lie flat and get watched, and that is deliberate rather than cautious box ticking. Pressure on the biopsy track and stillness give the small vessels time to seal, and the monitoring period exists because bleeding, when it happens, tends to declare itself early.
During that window the team checks pulse and blood pressure at set intervals, asks about back or shoulder pain, and inspects each urine sample for colour. A blood count is often repeated before discharge. Some centres scan the kidney with ultrasound afterwards to look for a collection of blood around it. Pink tinged urine on the first pass or two is something teams look for and expect to settle; clots are not, and they are reported straight away.
Research suggests that serious complications after a native kidney biopsy are uncommon, with most events being small collections of blood that cause no symptoms and resolve without any procedure 5. That is the reason the monitoring is measured in hours rather than days, and the reason nobody rushes you out of bed early.
Expect a dull ache at the site. Expect to be asked, repeatedly, whether the pain is staying the same or getting worse, because a pain that climbs is more informative than a pain that is simply there. Tell the nurse about dizziness when you first sit up, shoulder tip pain, or a feeling of fullness in the back, rather than waiting to see whether it passes.
Recovery is quiet, short and front loaded with restrictions. Most people feel sore around the site for several days and tired for a day or two, and then feel normal.
The standard advice is to avoid heavy lifting, straining and hard training until your team clears you, because a sudden rise in abdominal pressure is exactly the kind of stress a healing biopsy track does not need. Walking is usually encouraged early. Driving waits until you are off any sedating medicine and can brake hard without flinching. Your care team sets the dates for returning to the gym, to contact sport and to physical work, and those dates depend on what was found and how the procedure went, so take them from the people who did it.
Drink normally unless you have been told to restrict fluid. Keep the dressing dry for as long as you were instructed, and look at the site once a day for spreading redness, swelling or discharge.
Most importantly, know the signs that end the waiting. Blood clots in the urine, dizziness or feeling faint, back pain that is getting worse, fever, or difficulty passing urine all need urgent assessment. Call 911 or go to the emergency department for any of those.
Bleeding is the main risk, and it ranges from a bruise you never notice to an event that needs intervention. Smaller bleeds show up as a collection of blood around the kidney on a scan or as visible blood in the urine. Larger ones can need a blood transfusion, a procedure by a radiologist to block the bleeding vessel, or, very rarely, surgery.
In pooled analyses of native kidney biopsies, the procedure is associated with a small risk of bleeding that requires a transfusion, and with a smaller risk again of needing a procedure to stop the bleeding 6. Research suggests that the overall rate of major complications is low and that the majority of bleeding found after biopsy causes no symptoms at all 5.
Other recognised risks are less frequent. An abnormal connection can form between a small artery and vein in the kidney, which usually causes no trouble and often closes on its own. Infection at the site is possible, as it is with anything that crosses the skin. Pain that needs more than simple measures happens. Very occasionally the sample does not contain enough filtering units to answer the question, and the discussion about repeating it begins again.
Risk is not the same for everyone. It is shaped by blood pressure on the day, clotting, kidney size and scarring, body habitus, the needle used and the operator's experience, which is why the pre-procedure checks are not a formality. The right way to use these figures is as a frame for your own conversation, because a clinician who knows your bloodwork and your scan can say far more about your situation than any general range can.
Some situations make sampling through the skin unsuitable, either until something is corrected or altogether. Reviews of indications and contraindications list uncontrolled high blood pressure, a bleeding tendency or clotting results outside the acceptable window, active infection in the kidney or the overlying skin, small shrunken kidneys with heavy scarring, multiple cysts, an uncontrolled bleeding risk from medicines, and an inability to lie still or follow breathing instructions 2.
Several of those are temporary. Blood pressure can be brought down, clotting can be corrected, an infection can be cleared, and the biopsy can then be reconsidered. Others change the route rather than cancelling the plan. When bleeding risk is the obstacle, a transjugular approach is one of the options a team weighs, and research suggests it provides diagnostic tissue with a low rate of major bleeding in people chosen for it 4.
A single functioning kidney is treated as a special case rather than an automatic barrier, because the consequences of a serious bleed are greater when there is no second organ. Heavily scarred, shrunken kidneys raise a different question, since tissue from a kidney that is already end stage often shows scarring without revealing what caused it, which means the information gained may not justify the risk taken.
None of this is a decision to make from a list. It is a conversation with the nephrologist who ordered the test, and it is reasonable to ask directly what they expect the tissue to change.
In many centres, yes, for selected people. Studies suggest that a native kidney biopsy can be performed as a day case, with a defined period of monitored bed rest and observation before discharge, in people chosen on the basis of their bleeding risk and clinical stability 7.
The selection is the point. Day case pathways usually apply to people with acceptable clotting results, controlled blood pressure, no major additional bleeding risk, a reliable adult at home and the ability to return quickly if something changes. An overnight stay is more likely when kidney function is markedly reduced, when blood pressure has been difficult, when a complication appeared during the observation period, or when home circumstances make quick return difficult.
Either way, the same monitoring happens. The difference is where you sleep, not whether anyone is watching. If you are offered a day case biopsy, the useful questions are how long the observation period will be, what will be checked before you are allowed home, who to call overnight, and how far you should stay from a hospital for the next day.
Results describe the pattern in the tissue, how active it looks, and how much permanent scarring is already present. A report typically names the pattern of injury, notes immune deposits and where they sit, counts filtering units and the proportion that are scarred, and comments on the tubules, the tissue between them and the small vessels.
Turnaround varies, because the sample is processed in several ways and electron microscopy and specialist stains take longer than routine slides. Light microscopy and immunofluorescence often come back first, with a final report issued once everything is assembled. Rather than planning around a fixed number of days, ask the team who takes the sample when they expect the preliminary and final reports, and how the result will be communicated.
The way to read any result is in three steps. What the tissue shows, which is a description. What it may reflect, which is an interpretation made alongside your bloodwork, your urine findings and your history. And what to do next, which is a decision for a clinician, since management, including whether any therapy is appropriate, belongs to a licensed provider who has reviewed the whole picture.
A biopsy also sets a baseline. The amount of scarring recorded today is the reference point against which later kidney function is judged, and that context often matters as much as the name of the pattern.
A biopsy is one data point in a sequence, and the tests around it usually include a filtering estimate, a urine protein measure and a urine examination. Blood work typically covers creatinine with a calculated filtering rate, often cystatin C as a second estimate, plus electrolytes, calcium, phosphate, albumin and a full blood count.
Urine testing does the work that blood cannot. A urine albumin to creatinine ratio quantifies how much protein is leaking, and a repeated measure tracks whether the leak is growing or shrinking. A urine sample examined under a microscope can show red cell casts and abnormally shaped red cells, which point towards inflammation inside the filtering units rather than bleeding from further down the urinary tract. Markers of inflammation and specific immune antibodies are sometimes added when a systemic illness is suspected, and imaging confirms that both kidneys are present, of reasonable size and not obstructed.
These tests also decide how a biopsy result is used afterwards. Protein in the urine and filtering function are the measures followed over time to see whether what the tissue showed is settling or progressing, which is why having good pre-biopsy values recorded is genuinely useful.
Speak to a clinician promptly about any kidney result that sits outside the range on your report, any new or persistent protein or blood in the urine, and any unexplained drop in filtering function, even when you feel completely well. Kidney disease is quiet for a long time, and feeling fine is not reassurance.
After a biopsy, the urgent signs are specific. Call 911 or go to the emergency department if you pass blood clots in your urine, feel dizzy or faint, develop back or flank pain that is getting worse, cannot pass urine, or develop a fever. Those signs need emergency assessment, not a wait and see approach.
Less urgent but still worth a call to the team who performed the procedure are persistent soreness that is not improving, redness or discharge at the site, and any uncertainty about when to restart a medicine that was paused. This article is educational and is not medical advice. Discuss your own results, your preparation and any treatment decision with a clinician or licensed provider who knows your history.
Related reading on kidney testing: what blood tests check kidney function walks through the blood panel behind a filtering estimate, and the uacr test guide explains the urine ratio used to measure and track protein leak.
The sampling itself is brief, often only a few minutes once you are positioned and numbed. The appointment is much longer because of consent, checks, numbing time and the monitoring period afterwards, so plan for most of the day. Your team can tell you how long their observation window runs before discharge.
Most people describe pressure and a deep push rather than sharp pain, because the skin and the tissue below it are numbed first. There is usually a loud click as the needle fires. A dull ache at the site for a few days afterwards is common, and worsening pain should be reported straight away.
Usually not. A kidney biopsy is normally done awake with local numbing, because you need to hold your breath on command while the sample is taken. Light sedation is used in some cases, and the team will tell you in advance which approach they plan to use.
Some medicines are paused before the procedure and some are continued, and the answer depends on why you take them. Ask your prescriber well before the appointment and never stop anything on your own. Bring a complete list, including anything you buy without a prescription, so the team can check it.
A pink tinge on the first urine samples is something teams watch for and expect to settle. Passing visible blood clots is different and is reported immediately. If you pass clots, feel dizzy or faint, or your back pain is getting worse, call 911 or go to the emergency department.
Heavy lifting, straining and hard training are held off until your care team clears you, because a sudden rise in abdominal pressure stresses the healing biopsy track. Walking is usually encouraged early. Ask for a specific date before you leave, since it depends on how the procedure went.
No. Blood and urine tests show how well the kidneys are filtering and how much protein is leaking, but they cannot show the pattern of injury inside the tissue. A biopsy is suggested when that pattern would change what a clinician does next, and the clinician decides when tissue is needed.
Timing varies because the sample is processed in several ways, and some of that laboratory work takes longer than routine slides. A preliminary report often arrives before the final one. Ask the team who takes the sample when each report is expected and how the result will be given to you.